Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
Tremfya (Guselkumab)
General Medication Fact Sheet for Tremfya
| Field | Information |
|---|---|
| Medication Name | Tremfya |
| Generic Name | Guselkumab |
| Purpose | Treatment of moderate to severe plaque psoriasis and active psoriatic arthritis. |
| Mechanism of Action | Selective interleukin-23 (IL-23) inhibitor. It binds to the p19 subunit of IL-23, preventing it from binding to its receptor and inhibiting the release of pro-inflammatory cytokines. |
| Dosage Forms | Subcutaneous injection |
| Available Strengths | 100 mg/mL |
| Dosage Frequency | Initially, two injections 4 weeks apart, followed by one injection every 8 weeks. |
| Common Side Effects | Upper respiratory infections, headache, injection site reactions, joint pain, diarrhea, gastroenteritis, tinea infections. |
| Serious Side Effects | Serious infections (bacterial, fungal, or viral), allergic reactions (hives, difficulty breathing, swelling of face, lips, tongue, or throat), tuberculosis (TB) reactivation. |
| Drug Interactions | Live vaccines (avoid), CYP450 substrates (potential interaction due to altered cytokine levels). |
| Important Notes | Inform your doctor if you have an infection, are planning to receive any vaccinations, or have a history of tuberculosis. Evaluate for TB infection prior to initiating treatment. |
| Storage | Store in the refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. If necessary, Tremfya may be stored at room temperature up to 30°C (86°F) for a single period of up to 30 days. Once stored at room temperature, do not return to refrigerator; discard if not used within 30 days. |
| Missed Dose | Administer the injection as soon as you remember, then continue with your regular schedule. Contact your healthcare provider for guidance. |
| Alternatives | Cosentyx (secukinumab), Stelara (ustekinumab), Skyrizi (risankizumab), Enbrel (etanercept) |
Tremfya Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Cosentyx (secukinumab) | IL-17A inhibitor | Another biologic used for plaque psoriasis and psoriatic arthritis. |
| Stelara (ustekinumab) | IL-12 and IL-23 inhibitor | Biologic option for psoriasis and psoriatic arthritis; targets different interleukins than Tremfya. |
| Skyrizi (risankizumab) | IL-23 inhibitor | Similar mechanism of action to Tremfya. |
| Enbrel (etanercept) | TNF-alpha inhibitor | A different class of biologic that can be used for psoriatic arthritis and psoriasis. |
Tremfya Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Upper respiratory infections | Serious infections (bacterial, fungal, viral) |
| Headache | Allergic reactions (hives, difficulty breathing, swelling) |
| Injection site reactions (redness, pain, swelling) | Tuberculosis (TB) reactivation |
| Joint Pain | New or worsening inflammatory bowel disease (Crohn’s disease or ulcerative colitis) |
Tremfya Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Plaque Psoriasis | 100 mg | 100 mg subcutaneously at weeks 0, 4, and every 8 weeks thereafter | Administered by subcutaneous injection. Rotate injection sites with each dose. |
| Psoriatic Arthritis | 100 mg | 100 mg subcutaneously at weeks 0, 4, and every 8 weeks thereafter | Administered by subcutaneous injection. Can be used alone or in combination with a DMARD. |
